Nektar Therapeutics Statistics
Share Statistics
Nektar Therapeutics has 186.1M
shares outstanding. The number of shares has increased by 1.13%
in one year.
| Shares Outstanding | 186.1M |
| Shares Change (YoY) | 1.13% |
| Shares Change (QoQ) | 0.89% |
| Owned by Institutions (%) | 63.51% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 307 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 8.14M, so 4.37% of the outstanding
shares have been sold short.
| Short Interest | 8.14M |
| Short % of Shares Out | 4.37% |
| Short % of Float | 5.57% |
| Short Ratio (days to cover) | 2.33 |
Valuation Ratios
The PE ratio is -1.61 and the forward
PE ratio is -0.93.
Nektar Therapeutics's PEG ratio is
0.03.
| PE Ratio | -1.61 |
| Forward PE | -0.93 |
| PS Ratio | 1.94 |
| Forward PS | 0.6 |
| PB Ratio | 3.15 |
| P/FCF Ratio | -1.08 |
| PEG Ratio | 0.03 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Nektar Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.26,
with a Debt / Equity ratio of 1.69.
| Current Ratio | 4.26 |
| Quick Ratio | 4.26 |
| Debt / Equity | 1.69 |
| Debt / EBITDA | -1.18 |
| Debt / FCF | -0.58 |
| Interest Coverage | -3.74 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1,613,557.38 |
| Profits Per Employee | $-1,950,180.33 |
| Employee Count | 61 |
| Asset Turnover | 0.32 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -239K |
| Effective Tax Rate | 0.2% |
Stock Price Statistics
The stock price has increased by -62.8% in the
last 52 weeks. The beta is 0.63, so Nektar Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.63 |
| 52-Week Price Change | -62.8% |
| 50-Day Moving Average | 0.73 |
| 200-Day Moving Average | 1.04 |
| Relative Strength Index (RSI) | 40.02 |
| Average Volume (20 Days) | 2,469,713 |
Income Statement
In the last 12 months, Nektar Therapeutics had revenue of 98.43M
and earned -118.96M
in profits. Earnings per share was -0.58.
| Revenue | 98.43M |
| Gross Profit | 67.74M |
| Operating Income | -105.2M |
| Net Income | -118.96M |
| EBITDA | -86.7M |
| EBIT | -91.09M |
| Earnings Per Share (EPS) | -0.58 |
Full Income StatementBalance Sheet
The company has 44.25M in cash and 102.56M in
debt, giving a net cash position of -58.31M.
| Cash & Cash Equivalents | 44.25M |
| Total Debt | 102.56M |
| Net Cash | -58.31M |
| Retained Earnings | -3.6B |
| Total Assets | 303.85M |
| Working Capital | 199.89M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -175.71M
and capital expenditures -1.47M, giving a free cash flow of -177.18M.
| Operating Cash Flow | -175.71M |
| Capital Expenditures | -1.47M |
| Free Cash Flow | -177.18M |
| FCF Per Share | -0.86 |
Full Cash Flow StatementMargins
Gross margin is 68.82%, with operating and profit margins of -106.88% and -120.86%.
| Gross Margin | 68.82% |
| Operating Margin | -106.88% |
| Pretax Margin | -121.1% |
| Profit Margin | -120.86% |
| EBITDA Margin | -88.08% |
| EBIT Margin | -106.88% |
| FCF Margin | -180.01% |
